tiprankstipranks
Advertisement
Advertisement

Orexo updates share and voting structure after class C conversion

Story Highlights
  • Orexo AB now has 37,156,639 shares outstanding, with 35,127,056 ordinary shares and 2,029,583 class C shares, corresponding to 35,330,014.3 total votes.
  • The updated share and vote structure follows a February 2026 conversion of class C shares into ordinary shares, enhancing transparency for investors and governance assessments.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Orexo updates share and voting structure after class C conversion

Claim 30% Off TipRanks

The latest announcement is out from Orexo AB ( (SE:ORX) ).

Orexo AB has reported its updated share and vote structure as of the last trading day of March, confirming a total of 37,156,639 shares outstanding. Of these, 35,127,056 are ordinary shares carrying one vote each, while 2,029,583 are class C shares carrying one tenth of a vote per share, resulting in a total of 35,330,014.3 votes in the company.

The change in Orexo’s capital structure stems from a previously announced conversion of class C shares into ordinary shares, completed following the February 19, 2026 decision. By clarifying the composition of share classes and voting rights, the company provides greater transparency for investors and other stakeholders, which is particularly relevant for governance assessments and trading decisions in its Stockholm‑listed and U.S.‑traded securities.

The most recent analyst rating on (SE:ORX) stock is a Hold with a SEK21.00 price target. To see the full list of analyst forecasts on Orexo AB stock, see the SE:ORX Stock Forecast page.

More about Orexo AB

Orexo AB is a Swedish pharmaceutical company focused on treatments for severe diseases and life‑saving rescue medications. Its core innovation is AmorphOX, a proprietary drug delivery technology designed to improve bioavailability and stability for both large and small molecules, supporting new administration routes and more efficient manufacturing and distribution. With more than 30 years of experience and multiple globally approved drugs, Orexo runs a diversified pipeline of clinical and preclinical programs in collaboration with research, development, and commercialization partners. The company is headquartered in Uppsala, Sweden, and its shares are listed on Nasdaq Stockholm with American Depositary Receipts traded on the OTCQX market in the United States.

Average Trading Volume: 51,235

Technical Sentiment Signal: Sell

Current Market Cap: SEK754.3M

See more data about ORX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1